InvestSMART

Entropy Neurodynamics Limited (ASX:ENP)

ALERT: Price-sensitive ASX Announcement for ENP
Current share price for ENP : $0.034 -0.003 (-8.11%)+
Announcement
Release
5 May 2026 9:38AM
Price at Release
$0.037
Full Release
download
Summary
Entropy Neurodynamics Limited, a clinical-stage biotechnology company, has filed a new US Provisional Patent Application to advance its TRP-8803 irritable bowel syndrome (IBS) program. This filing complements an existing international patent application and is based on promising clinical data from a Phase 2a study demonstrating a 75% response rate in treatment-resistant IBS patients. The new patent aims to strengthen the company's intellectual property portfolio and support its US-focused development strategy. This initiative also aligns with the company's existing Australian patent, enhancing long-term exclusivity and strategic positioning in the treatment of gut-brain disorders.
Key Points
  • Entropy Neurodynamics Limited filed a US Provisional Patent Application No. 64/055,765.
  • The filing is in addition to an existing international patent application under the PCT.
  • The new filing is based on clinical insights from Phase 2a Clinical Study of TRP-8802.
  • The Phase 2a study showed a 75% response rate in treatment-resistant IBS patients.
  • The new patent would support Entropy's ongoing US-focused development strategy.
  • Potential patents will complement the existing Australian patent with protection through to 2042.
  • CEO Jason Carroll emphasised the strengthened IP position and strategic value of TRP-8803.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.